Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Sep;5(5):359-70.
doi: 10.1177/1756283X12450245.

Management of hepatitis B reactivation in patients receiving cancer chemotherapy

Yi-Wen Huang  1 , Raymond T Chung
Affiliations

Management of hepatitis B reactivation in patients receiving cancer chemotherapy

Yi-Wen Huang et al. Therap Adv Gastroenterol. 2012 Sep.

Abstract

Hepatitis B virus (HBV) reactivation is well documented in previously resolved or inactive HBV carriers who receive cancer chemotherapy. The consequences of HBV reactivation range from self-limited conditions to fulminant hepatic failure and death. HBV reactivation also leads to premature termination of chemotherapy or delay in treatment schedules. This review summarizes current knowledge of management of HBV reactivation in patients receiving cancer chemotherapy. HBV surface antigen (HBsAg) testing should be performed in patients who require cancer chemotherapy. Four meta-analyses support lamivudine prophylaxis for HBV reactivation during chemotherapy in HBsAg-positive patients. Randomized controlled trials to compare different HBV antiviral agents are needed to define optimal regimens for the prevention and treatment of HBV reactivation in patients receiving cancer chemotherapy.

Keywords: HBV reactivation; cancer; chemotherapy; hepatitis B virus; lamivudine; prophylaxis.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors declare no conflicts of interest in preparing this article.

Figures

Figure 1.
Figure 1.
Typical clinical course of HBV reactivation in HBsAg-positive and HBsAg-negative/anti-HBc-positive individuals receiving chemotherapy. In HBsAg-positive patients, serum HBV DNA was undetectable at the time of peak ALT, instead, it peaked prior to ALT by around 2 weeks [Yeo et al. 2001]. In HBsAg-negative/anti-HBc-positive subjects, serum HBV DNA preceded elevated ALT by 12–28 weeks [Hui et al. 2006]. HBsAg seroreversion developed after rise in serum HBV DNA and before ALT elevation [Hui et al. 2006]. HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen; ALT, alanine transaminase.
See this image and copyright information in PMC

References

    1. Alexopoulos C.G., Vaslamatzis M., Hatzidimitriou G. (1999) Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours. Br J Cancer 81: 69–74 - PMC - PubMed
    1. Artz A.S., Somerfield M.R., Feld J.J., Giusti A.F., Kramer B.S., Sabichi A.L., et al. (2010) American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol 28: 3199–3202 - PubMed
    1. Chang T.T., Gish R.G., de Man R., Gadano A., Sollano J., Chao Y.C., et al. (2006) A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354: 1001–1010 - PubMed
    1. Cheng J.C., Liu M.C., Tsai S.Y., Fang W.T., Jer-Min Jian J., Sung J.L. (2004) Unexpectedly frequent hepatitis B reactivation by chemoradiation in postgastrectomy patients. Cancer 101: 2126–2133 - PubMed
    1. Cheng A.L., Hsiung C.A., Su I.J., Chen P.J., Chang M.C., Tsao C.J., et al. (2003) Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 37: 1320–1328 - PubMed

LinkOut - more resources